{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:55:27Z","timestamp":1791309327411,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.diabres.2026.113580","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:39:45Z","timestamp":1790869185000},"page":"113580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FGF21 and GDF15 alongside conventional cardiac biomarkers in myocardial dysfunction and cardiovascular risk in type 2 diabetes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"242","author":[{"family":"Mustakin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liong Boy","family":"Kurniawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nurahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hermawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husaini","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meita","family":"Hendrianingtyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirul Reswara","family":"Ihza Makarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi Alfian","family":"Zainuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Dwiwahyuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansyur","family":"Arief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12933-022-01711-5","article-title":"Association of biomarkers and risk scores with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus","volume":"21","author":"Halabi","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.diabres.2026.113580_b0010","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/biomedicines12092031","article-title":"Subclinical left ventricular dysfunction over seven-year follow-up in type 2 diabetes patients without cardiovascular diseases","volume":"12","author":"Akasheva","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13098-021-00781-x","article-title":"Assessment of subclinical left ventricle myocardial dysfunction using global myocardial work in type 2 diabetes mellitus patients with preserved left ventricle ejection fraction","volume":"14","author":"Wang","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2026.113580_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.733339","article-title":"Quantitative analysis of myocardial work by non-invasive left ventricular pressure-strain loop in patients with type 2 diabetes mellitus","volume":"8","author":"Huang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabres.2026.113580_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-018-0782-0","article-title":"Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study","volume":"17","author":"Liu","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.diabres.2026.113580_b0030","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1007\/s00330-022-08800-9","article-title":"Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunction","volume":"32","author":"Liu","year":"2022","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0035","doi-asserted-by":"crossref","first-page":"13126","DOI":"10.1038\/s41598-020-69977-x","article-title":"Assessment of left ventricular deformation in patients with type 2 diabetes mellitus by cardiac magnetic resonance tissue tracking","volume":"10","author":"Xie","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.diabres.2026.113580_b0040","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/diagnostics11091577","article-title":"Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus","volume":"11","author":"Ianos","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"10.1016\/j.diabres.2026.113580_b0045","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/medicina60111841","article-title":"Predictive value of NT-proBNP, FGF21, galectin-3 and copeptin in advanced heart failure in patients with preserved and mildly reduced ejection fraction and type 2 diabetes mellitus","volume":"60","author":"Ianos","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.diabres.2026.113580_b0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-017-0588-5","article-title":"Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death","volume":"16","author":"Shen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113580_b0055","doi-asserted-by":"crossref","first-page":"33953","DOI":"10.1038\/srep33953","article-title":"Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction","volume":"6","author":"Chou","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.diabres.2026.113580_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","article-title":"Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up","volume":"101","author":"Lenart-Lipinska","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2026.113580_b0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","article-title":"The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate intervention and Event Lowering in Diabetes study","volume":"58","author":"Ong","year":"2015","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.diabres.2026.113580_b0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1253\/circrep.CR-25-0067","article-title":"Prognostic impact of fibroblast growth factor 21 in patients with heart failure","volume":"7","author":"Sunaga","year":"2025","journal-title":"Circ Rep"},{"issue":"6","key":"10.1016\/j.diabres.2026.113580_b0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005344","article-title":"Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus","volume":"6","author":"Lee","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.diabres.2026.113580_b0080","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.amjcard.2014.06.020","article-title":"Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus","volume":"114","author":"Dominguez-Rodriguez","year":"2014","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113580_b0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00125-022-05678-6","article-title":"Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study","volume":"65","author":"Echouffo-Tcheugui","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.diabres.2026.113580_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101380","article-title":"Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: findings from Da Qing IGT and diabetes study","volume":"48","author":"Qian","year":"2022","journal-title":"Diabetes Metab"},{"issue":"24","key":"10.1016\/j.diabres.2026.113580_b0095","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1136\/heartjnl-2015-308949","article-title":"Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes","volume":"102","author":"Resl","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/03009734.2019.1696430","article-title":"Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach","volume":"125","author":"Carlsson","year":"2020","journal-title":"Ups J Med Sci"},{"issue":"4","key":"10.1016\/j.diabres.2026.113580_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196634","article-title":"Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - an observational follow-up study","volume":"13","author":"Frimodt-M\u00f8ller","year":"2018","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.diabres.2026.113580_b0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021661","article-title":"Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS trial","volume":"10","author":"Sen","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012797","article-title":"Clinical and biomarker predictors of expanded heart failure outcomes in patients with type 2 diabetes mellitus after a recent acute coronary syndrome: insights from the EXAMINE trial","volume":"9","author":"Sharma","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2026.113580_b0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039129","article-title":"Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on neurohumoral and mitochondrial activation in patients with diabetes","volume":"14","author":"Ikonomidis","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.diabres.2026.113580_b0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12872-024-03810-5","article-title":"Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study","volume":"24","author":"Iyer","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"10.1016\/j.diabres.2026.113580_b0130","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/ejhf.3576","article-title":"Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: a 20-year follow-up study","volume":"27","author":"Monzo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabres.2026.113580_b0135","volume":"236","author":"Mustakin","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2026.113580_b0140","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.diabres.2026.113580_b0145","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.diabres.2026.113580_b0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113580_b0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113580_b0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.diabres.2026.113580_b0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.diabres.2026.113580_b0170","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024). Cochrane; 2024. Available from: https:\/\/www.cochrane.org\/handbook."},{"issue":"10","key":"10.1016\/j.diabres.2026.113580_b0175","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2026.113580_b0180","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist","volume":"370","author":"Salameh","year":"2020","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.diabres.2026.113580_b0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.diabres.2026.113580_b0190","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113580_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"449","key":"10.1016\/j.diabres.2026.113580_b0200","first-page":"89","article-title":"A nonparametric trim and fill method of accounting for publication bias in meta-analysis","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:40:56Z","timestamp":1791308456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726005000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":40,"alternative-id":["S0168822726005000"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113580","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGF21 and GDF15 alongside conventional cardiac biomarkers in myocardial dysfunction and cardiovascular risk in type 2 diabetes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113580"}}